Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
EMA says bamlanivimab can be considered as monotherapy treatment for COVID-19 » 11:16
03/05/21
03/05
11:16
03/05/21
11:16
LLY

Eli Lilly

$203.63 /

+3.06 (+1.53%)

The EMA's human…

The EMA's human medicines committee, or CHMP, has completed its review on the use of Eli Lilly's monoclonal antibodies bamlanivimab and etesevimab to treat patients with COVID-19, announced the EMA. "The Agency concluded that bamlanivimab and etesevimab can be used together to treat confirmed COVID-19 in patients who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe. The Agency also looked at the use of bamlanivimab alone and concluded that, despite uncertainties around the benefits of monotherapy, it can be considered a treatment option," the EMA announced. Reference Link

ShowHide Related Items >><<
LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

Hot Stocks
Eli Lilly research and development group publishes pirtobrutinib trial data » 06:48
03/05/21
03/05
06:48
03/05/21
06:48
LLY

Eli Lilly

$200.53 /

-1.42 (-0.70%)

Loxo Oncology at Lilly, a…

Loxo Oncology at Lilly, a research and development group of Eli Lilly, announced that The Lancet has published data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in relapsed or refractory chronic lymphocytic leukemia, or CLL, small lymphocytic lymphoma, or SLL, mantle cell lymphoma, or MCL and other non-Hodgkin's lymphomas. Pirtobrutinib is an investigational, highly selective, non-covalent Bruton's tyrosine kinase, or BTK, inhibitor. The data in the publication include key findings previously presented at the 2020 American Society of Hematology. The publication includes safety and efficacy data for 323 relapsed or refractory patients that were enrolled to the BRUIN Phase 1/2 trial as of September 27, 2020.

ShowHide Related Items >><<
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:55
03/05/21
03/05
04:55
03/05/21
04:55
LLY

Eli Lilly

$200.53 /

-1.42 (-0.70%)

Analysts discuss Eli…

Analysts discuss Eli Lilly's Alzheimer's Disease Drug, Donanemab and the real-world clnical implications with Paul R. Solomon, PhD on an Analyst/Industry conference call to be held on March 5.

ShowHide Related Items >><<
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

Thursday
Hot Stocks
Biogen to build gene therapy manufacturing center in North Carolina » 07:57
03/04/21
03/04
07:57
03/04/21
07:57
BIIB

Biogen

$266.84 /

-3.2 (-1.19%)

Biogen announced its…

Biogen announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas. Through the new facility, Biogen aims to continue its investment in North Carolina and expand its existing operations and combined workforce of approximately 1,900 employees at both campuses in RTP. Biogen anticipates that the new facility will create approximately 90 new jobs, with an estimated total investment of approximately $200 million. Biogen selected RTP for this new facility given the region's diverse pool of talent and the company's 26-year track record of attracting highly qualified and passionate employees in North Carolina. Biogen's priority is to continue to foster and enable a diverse and inclusive workforce - representing age, gender, sexual identity, race, ethnicity, Veterans, and people with disabilities - that reflects the communities where we operate and the patients who we serve. The site will be 175,000 square feet and designed in compliance with the most advanced sustainability standards regarding energy use, waste management and water consumption.

ShowHide Related Items >><<
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

Hot Stocks
Dyne Therapeutics appoints Wildon Farwell as CMO » 07:30
03/04/21
03/04
07:30
03/04/21
07:30
DYN

Dyne Therapeutics

$16.73 /

-1.02 (-5.75%)

, BIIB

Biogen

$266.84 /

-3.2 (-1.19%)

Dyne Therapeutics (DYN)…

Dyne Therapeutics (DYN) announced the appointment of Wildon Farwell, M.D., MPH, as CMO. Dr. Farwell joins Dyne from Biogen (BIIB), where he was vice president, global head of neuromuscular diseases, medical affairs.

ShowHide Related Items >><<
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

  • 21
    Jan
  • 17
    Sep
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

Hot Stocks
Eli Lilly announces results from SURPASS-2 clinical trial » 06:58
03/04/21
03/04
06:58
03/04/21
06:58
LLY

Eli Lilly

$201.93 /

-2.24 (-1.10%)

Tirzepatide led to…

Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly's 40-week SURPASS-2 clinical trial. In topline results from the largest SURPASS trial to date, using the efficacy estimand, the highest dose of tirzepatide reduced A1C by 2.46% and body weight by 12.4 kg. The lowest dose of tirzepatide reduced A1C by 2.09% and body weight by 7.8 kg compared to semaglutide at 1.86% and 6.2 kg. Additionally, 51% of those taking tirzepatide 15 mg achieved an A1C of less than 5.7%- the level seen in people without diabetes - compared to 20% of those taking semaglutide. The overall safety profile of tirzepatide was similar to previously reported SURPASS trials and the well-established glucagon-like peptide-1, or GLP-1, receptor agonist class. Across all treatment arms, the most commonly reported adverse events were gastrointestinal-related. Tirzepatide is a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide, or GIP, and GLP-1 receptor agonist that integrates the actions of both incretins into a single molecule, representing a new class of medicines being studied for the treatment of type 2 diabetes. Semaglutide is a GLP-1 receptor agonist for the treatment of type 2 diabetes. SURPASS-2 was a 40-week, randomized, open-label trial comparing the efficacy and safety of tirzepatide to semaglutide as an add-on to metformin in adults with type 2 diabetes. The study randomized 1,879 participants, who had a mean duration of diabetes of 8.6 years, a baseline A1C of 8.28% and a baseline weight of 93.7 kg. Across both estimands, all three doses of tirzepatide delivered superior A1C and body weight reductions compared to semaglutide. Of the participants receiving tirzepatide 15 mg, 92% achieved an A1C of less than 7%, the American Diabetes Association's recommended target for people with diabetes, compared to 81% of those taking semaglutide. In the treatment-regimen estimand, all three doses of tirzepatide delivered superior A1C and body weight reductions compared to semaglutide. Greater percentages of participants achieved an A1C of less than 7% across all three doses compared to semaglutide, with statistical significance met for 10 mg and 15 mg but not for 5 mg. Hypoglycemia less than 54 mg/dL was reported in 0.6%, 0.2% and 1.7% of participants in the tirzepatide arms and in 0.4% of participants in the semaglutide arm. The most commonly reported adverse events across all treatment arms were gastrointestinal-related, including nausea, diarrhea and vomiting. Treatment discontinuation rates due to adverse events were 5.1%, 7.7%, 7.9% and 3.8%.

ShowHide Related Items >><<
LLY Eli Lilly
$201.93 /

-2.24 (-1.10%)

LLY Eli Lilly
$201.93 /

-2.24 (-1.10%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$201.93 /

-2.24 (-1.10%)

LLY Eli Lilly
$201.93 /

-2.24 (-1.10%)

LLY Eli Lilly
$201.93 /

-2.24 (-1.10%)

LLY Eli Lilly
$201.93 /

-2.24 (-1.10%)

Wednesday
Hot Stocks
Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint » 06:51
03/03/21
03/03
06:51
03/03/21
06:51
LLY

Eli Lilly

$204.13 /

-2.26 (-1.10%)

, INCY

Incyte

$78.57 /

-1.12 (-1.41%)

Eli Lilly (LLY) and…

Eli Lilly (LLY) and Incyte (INCY) announced top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata, or AA. Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received breakthrough therapy designation from the FDA for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint. There are currently no FDA-approved treatments for AA. This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool, or SALT, score of 50 and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S. Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis, or RA, and atopic dermatitis, or AD. No deaths, major adverse cardiovascular events, or MACE, or venous thromboembolic events, or VTEs, were reported in the study. BRAVE-AA2 is the first Phase 3 study with "positive" results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD. Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as Olumiant in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus, juvenile idiopathic arthritis and COVID-19.

ShowHide Related Items >><<
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
INCY Incyte
$78.57 /

-1.12 (-1.41%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

Tuesday
Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 13:01
03/02/21
03/02
13:01
03/02/21
13:01
LLY

Eli Lilly

$207.50 /

+1.11 (+0.54%)

Analysts discuss Eli…

Analysts discuss Eli Lilly's Alzheimer's Disease Drug, Donanemab and the real-world clnical implications with Paul R. Solomon, PhD on an Analyst/Industry conference call to be held on March 5.

ShowHide Related Items >><<
LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

LLY Eli Lilly
$207.50 /

+1.11 (+0.54%)

Recommendations
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan » 07:01
03/02/21
03/02
07:01
03/02/21
07:01
LLY

Eli Lilly

$206.39 /

+1.45 (+0.71%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott sees a positive risk/reward on Eli Lilly into the Phase 2 donanemab data presentation for the TRAILBLAZER-ALZ study with shares potentially up 5%-10% assuming results that suggest a high probability of eventual approval for the drug. This would include statistical significance on CDR-SB coupled with plaque reduction and Alzheimer's disease progression model data suggesting "clear and rapid efficacy of the drug," Schott tells investors in a research note. The analyst sees this outcome as a high probability event based on Eli Lilly's commentary and keeps an Overweight rating on the shares with a $240 price target.

ShowHide Related Items >><<
LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

LLY Eli Lilly
$206.39 /

+1.45 (+0.71%)

Monday
Conference/Events
Cantor Fitzgerald biopharma analysts hold an analyst/industry conference call » 15:48
03/01/21
03/01
15:48
03/01/21
15:48
ADVM

Adverum Biotechnologies

$13.31 /

+0.455 (+3.54%)

, UBX

Unity Biotechnology

$7.53 /

+0.7 (+10.25%)

, AGTC

Applied Genetic

$5.64 /

+0.54 (+10.59%)

, JNJ

Johnson & Johnson

$159.50 /

+1.08 (+0.68%)

, MGTX

MeiraGTx

$15.21 /

+0.4 (+2.70%)

, NITE

Nightstar Therapeutics

$25.41 /

+ (+0.00%)

, BIIB

Biogen

$272.79 /

-0.16 (-0.06%)

, AERI

Aerie Pharmaceuticals

$19.36 /

+0.96 (+5.22%)

, ALDX

Aldeyra

$12.20 /

-0.05 (-0.41%)

Biopharmaceuticals…

Biopharmaceuticals Analyst Chen, along with Dr. Ruchita Amin, Retina Specialist at Retina Vitreous Associates and Dr. Roger Goldberg, Partner and Vitreoretinal Surgeon at Bay Area Retina Associates, discuss hot topics and key 2021 focus areas in eye diseases on an Analyst/Industry Conference Call to be held on March 8 at 1 pm.

ShowHide Related Items >><<
UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

MGTX MeiraGTx
$15.21 /

+0.4 (+2.70%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

ADVM Adverum Biotechnologies
$13.31 /

+0.455 (+3.54%)

ADVM Adverum Biotechnologies
$13.31 /

+0.455 (+3.54%)

12/15/20 UBS
Adverum Biotechnologies initiated with a Neutral at UBS
11/15/20 Piper Sandler
Adverum Biotechnologies shares should grind higher over time, says Piper Sandler
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform from Underperform at Raymond James
11/12/20 Raymond James
Adverum Biotechnologies upgraded to Market Perform at Raymond James
UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

02/16/21 Citi
Unity Biotechnology downgraded to Sell from Neutral at Citi
08/18/20
Fly Intel: Top five analyst downgrades
08/18/20 Morgan Stanley
Unity Biotechnology downgraded at Morgan Stanley as UBX101 doesn't meet endpoint
08/18/20 Citi
Unity Biotechnology downgraded to Neutral from Buy at Citi
AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
02/01/21 Roth Capital
Applied Genetic price target raised to $35 from $30 at Roth Capital
11/17/20 Roth Capital
Applied Genetic price target raised to $30 from $26 at Roth Capital
11/11/20 H.C. Wainwright
Applied Genetic XLRP data 'continue to impress,' says H.C. Wainwright
JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MGTX MeiraGTx
$15.21 /

+0.4 (+2.70%)

02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
NITE Nightstar Therapeutics
$25.41 /

+ (+0.00%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

11/09/20 H.C. Wainwright
Aerie Pharmaceuticals price target lowered to $29 from $31 at H.C. Wainwright
10/28/20 H.C. Wainwright
Aerie Pharmaceuticals $50M upfront should reduce overhang, says H.C. Wainwright
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
10/19/20 BofA
Aerie Pharmaceuticals downgraded to Underperform from Neutral at BofA
ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

02/08/21 H.C. Wainwright
Aldeyra initiated with a Buy at H.C. Wainwright
01/28/21 JonesTrading
Aldeyra assumed with a Buy at JonesTrading
01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

MGTX MeiraGTx
$15.21 /

+0.4 (+2.70%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

ADVM Adverum Biotechnologies
$13.31 /

+0.455 (+3.54%)

  • 28
    Jan
  • 14
    Jan
  • 19
    Nov
  • 13
    Aug
JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

UBX Unity Biotechnology
$7.53 /

+0.7 (+10.25%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

ALDX Aldeyra
$12.20 /

-0.05 (-0.41%)

AGTC Applied Genetic
$5.64 /

+0.54 (+10.59%)

AERI Aerie Pharmaceuticals
$19.36 /

+0.96 (+5.22%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

JNJ Johnson & Johnson
$159.50 /

+1.08 (+0.68%)

BIIB Biogen
$272.79 /

-0.16 (-0.06%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.